Sareum (LON:SAR) Releases Quarterly Earnings Results

Sareum (LON:SAR) released its quarterly earnings data on Thursday. The company reported GBX (1.20) EPS for the quarter, Digital Look Earnings reports.

Sareum Trading Down 7.1%

Shares of LON SAR traded down GBX 1 during trading hours on Thursday, reaching GBX 13. The stock had a trading volume of 75,159 shares, compared to its average volume of 221,740. Sareum has a 52-week low of GBX 9.50 and a 52-week high of GBX 29. The business’s fifty day moving average price is GBX 17.44 and its two-hundred day moving average price is GBX 17.62. The firm has a market cap of £17.95 million, a price-to-earnings ratio of -3.61 and a beta of -1.08.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.